Literature DB >> 9682332

The effectiveness and safety of vaccines against human anthrax: a systematic review.

V Demicheli1, D Rivetti, J J Deeks, T Jefferson, M Pratt.   

Abstract

We report on the results of a systematic review of existing controlled clinical trials undertaken to assess the effectiveness and safety of vaccines against human anthrax in relation to disease incidence and side-effects. Two articles retrieved by electronic and hand search fulfilling some of the inclusion criteria underwent a quality assessment by a group of reviewers. Data synthesized from the two trials showed that estimates of overall effectiveness and safety favour treatment (overall odds ratio 0.16; 95% confidence interval 0.07-0.34). The route of inoculation appears to make little difference to the effectiveness of the vaccines; however, one study shows that the incidence and severity of side-effects are significantly higher with the killed vaccine than with the alum-based placebo (overall odds ratio 0.16; 95% confidence interval 2.38-27.17).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682332     DOI: 10.1016/s0264-410x(98)00023-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Anthrax: A disease of biowarfare and public health importance.

Authors:  Ajay Kumar Goel
Journal:  World J Clin Cases       Date:  2015-01-16       Impact factor: 1.337

Review 2.  Review of anthrax: A disease of farm animals.

Authors:  Md Emtiaj Alam; Md Mostofa Kamal; Moizur Rahman; Aurangazeb Kabir; Md Shafiqul Islam; Jayedul Hassan
Journal:  J Adv Vet Anim Res       Date:  2022-06-30

3.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

Authors:  S D Klas; C R Petrie; S J Warwood; M S Williams; C L Olds; J P Stenz; A M Cheff; M Hinchcliffe; C Richardson; S Wimer
Journal:  Vaccine       Date:  2008-08-12       Impact factor: 3.641

4.  Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen.

Authors:  Jon Oscherwitz; Fen Yu; Jana L Jacobs; Te-Hui Liu; Philip R Johnson; Kemp B Cease
Journal:  Infect Immun       Date:  2009-06-01       Impact factor: 3.441

5.  Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.

Authors:  Te-Hui Liu; Jon Oscherwitz; Bruce Schnepp; Jana Jacobs; Fen Yu; Kemp B Cease; Philip R Johnson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

6.  Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin.

Authors:  Julia Y Wang; Michael H Roehrl
Journal:  Med Immunol       Date:  2005-03-24

7.  Contribution of cryptic epitopes in designing a group A streptococcal vaccine.

Authors:  Victoria Ozberk; Manisha Pandey; Michael F Good
Journal:  Hum Vaccin Immunother       Date:  2018-06-14       Impact factor: 3.452

8.  Immunologic response of unvaccinated workers exposed to anthrax, Belgium.

Authors:  Pierre Wattiau; Marc Govaerts; Dimitrios Frangoulidis; David Fretin; Esther Kissling; Mieke Van Hessche; Bernard China; Martine Poncin; Yvo Pirenne; Germaine Hanquet
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.